Clinical Trials Logo

Chikungunya Fever clinical trials

View clinical trials related to Chikungunya Fever.

Filter by:

NCT ID: NCT04440774 Completed - Chikungunya Clinical Trials

Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.

Start date: October 23, 2020
Phase: Phase 1
Study type: Interventional

Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan area of Monterrey (Mexico), will be recruited as participants

NCT ID: NCT04434846 Completed - Dengue Fever Clinical Trials

Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia

Start date: February 8, 2021
Phase:
Study type: Observational

Background: Zika, dengue, and chikungunya are spread by mosquitos. These diseases have a major impact on public health. This is especially true in in Southeast Asia. Non-human primates (such as macaques) could play an essential role in spreading these diseases. Researchers want to further understand the relationship between humans and these primates. They want to see how this affects how mosquito-borne viruses are spread in Southeast Asia. Objective: To describe the prevalence of Zika virus, dengue virus, and chikungunya virus in the blood of people who live close to long-tailed macaques in Thailand and Cambodia. Eligibility: Healthy people aged 18-55 who have lived or worked within approximately 10 kilometers of the Wat Amphae Phnom monkey habitat in Kampong Speu, Cambodia, for a minimum of 2 years Design: Participation will last 1 day. Participants will be screened in person through an interview. Their medical history will be reviewed. Participants will give information about themselves. This will include sex, age, and behaviors related to the spread of mosquito-borne disease. For example, they will be asked about the number of water containers at their home. They will be asked about recent travel. They will be asked about the extent of their contact with the macaques. Participants will give a blood sample....

NCT ID: NCT03992872 Completed - Chikungunya Clinical Trials

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

WRAIR
Start date: November 20, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 parallel-group age- and gender-matched open label study in healthy adults 18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317) in prior recipients of other alphavirus vaccines versus alphavirus naïve controls.

NCT ID: NCT03829384 Completed - Clinical trials for Prevention of Chikungunya Virus Infection

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

Start date: January 22, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects. Cohorts of mRNA-1944 are planned to be investigated in a sequential dose escalation manner.

NCT ID: NCT03807843 Completed - Clinical trials for Chikungunya Virus Infection

Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

Start date: July 16, 2019
Phase: Phase 2
Study type: Interventional

Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.

NCT ID: NCT03690648 Completed - Chikungunya Fever Clinical Trials

Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya

CHIKGENE
Start date: August 1, 2018
Phase:
Study type: Observational

Chikungunya virus (CHIKV) infection has become a threat to public health worldwide. Reunion Island, due to the 2005-2006 epidemic, has acquired unique expertise and remains at the forefront of global research on this disease. The idea of genetic determinism of the clinical expression of infectious diseases has been supported by many epidemiological arguments over the past fifty years. The identification of genetic variants, associated with a disease, often allows a better understanding of the molecular mechanisms involved with consequent significant benefits such as the development of specific biomarkers for new preventive (vaccination) and / or therapeutic (drug design) approaches. In the absence of well-documented hypotheses about the genes potentially involved in the occurrence or evolution of a disease, genome-wide association studies (GWAS), whole genome, of nucleotide polymorphisms (SNPs) and the principle of linkage disequilibrium, under the commonly accepted hypothesis that the expression of a common disease is based on a small number of alleles commonly found in the population (frequency of minor allele greater than 1-5%), have become a method of choice, free of hypothesis, to specify the part of heritability of a complex disease and to identify its genetic determinants. Several epidemiological arguments support a significant proportion of genetic determinism in the explanation of the evolutionary pattern of Chikungunya, whose proportion of chronic forms can reach 40-60% in population-based studies conducted in the two years following an epidemic: - There are few risk factors associated with chronic forms and these appear to be unclear (age, comorbidities with several elements of the metabolic syndrome) or inconsistent (immune burden) in population studies; - The incidence of severe or atypical forms is rare in the order of 1% of infections; - In contrast to the acute phase (J1-J21) for which there seems to be a role of the viral load intensity and a consensual pro-inflammatory immune signature according to a recent meta-analysis]; The role of the intensity of the viral load in the pathogenesis of chronic arthralgia (> J90) and their immune signature remain to be determined, the latter being rather nonspecific, according to studies conducted in Reunion, Italy or Singapore. These elements justify the interest of a GWAS in the Chikungunya to identify new avenues and mechanistic hypotheses likely to explain the chronic arthralgia characteristic of the disease.

NCT ID: NCT03635086 Completed - Clinical trials for Chikungunya Virus Infection

Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)

Start date: August 22, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate immunogenicity and safety of Measles Virus-Chikungunya (MV-CHIK) vaccine in different dose regimens, 28 days after one or two vaccinations.

NCT ID: NCT03631719 Completed - Dengue Clinical Trials

Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia

WMP-COL
Start date: October 25, 2017
Phase:
Study type: Observational [Patient Registry]

Study setting: Medellin and Bello municipalities, Colombia Health condition(s) studied: Dengue, Zika and chikungunya virus infection Intervention: Deployment of Wolbachia-infected Aedes aegypti mosquitoes in Medellin and Bello. Study design: 1. An interrupted time-series analysis utilising routine disease surveillance data collected by the Medellín and Bello Health Secretariats, which aims to compare incidence of dengue, chikungunya and Zika pre- and post-Wolbachia release. 2. A test-negative study using an incident case-control design, which aims to quantify the reduction in disease incidence among people living within a Wolbachia-treated zone compared with an untreated zone that has a similar dengue risk profile at baseline.

NCT ID: NCT03590392 Completed - Chikungunya Fever Clinical Trials

Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)

Start date: July 31, 2018
Phase: Phase 1
Study type: Interventional

A phase I dose escalation study to assess the safety and immunogenicity of the candidate vaccine ChAdOx1 Chik in healthy volunteers. Volunteers will be recruited and vaccinated in Oxford, England. All vaccinations will be administered intramuscularly. Three different doses will be tested (5x10^9 vp, 2.5x10^10 vp and 5x10^10vp). The total duration of the study will be 26 weeks from the day of enrolment for all volunteers.

NCT ID: NCT03483961 Completed - Clinical trials for Chikungunya Virus Infection

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Start date: April 18, 2018
Phase: Phase 2
Study type: Interventional

The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults. Primary Objective: To assess the immune response to the vaccine Secondary Objectives: To assess the kinetics of the immune response to different doses/formulations/schedules To assess the persistence of immune responses to different doses/formulations/schedules To assess the effect of a booster dose of the vaccine Safety Objective: To assess local and systemic reactions to the vaccine and to describe the safety profile of the vaccine